BioAge Labs, Inc. reported $10M of revenue over the trailing twelve months, +168% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $10M (to Q2 2026). Net income: −$94M, trailing twelve months to Q2 2026. Free cash flow: −$88M, trailing twelve months to Q2 2026. Operating margin: −1041%, trailing twelve months to Q2 2026.

BIOABioAge Labs, Inc.

Healthcare

$6.35+30% 1Y

$6.35

$4.9452 weeks$24.29

BIOA as reported

BioAge Labs, Inc. reported $10M of revenue over the trailing twelve months, +168% on the year before. 9 reported series are charted on this page, each one as filed.

$10M

Revenue, trailing twelve months · to Q2 2026 · +168% against the twelve months before

Net income: −$94M
Net income · +20% year on year · trailing twelve months to Q2 2026
Free cash flow: −$88M
Free cash flow · +51% year on year · trailing twelve months to Q2 2026
Operating margin: −1041%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BIOA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$10M	+168%	Q2 2026
Net income	−$94M	+20%	Q2 2026
EPS	−$2.38	−132%	Q2 2026
Operating margin	−1041%	n/a	Q2 2026
Net margin	−923%	n/a	Q2 2026
ROE	−26%	n/a	Q2 2026
ROA	−25%	n/a	Q2 2026
ROIC	3787%	n/a	Q2 2026
Free cash flow	−$88M	+51%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.